NovoCure Ltd [NASDAQ: NVCR] price plunged by -24.05 percent to reach at -$3.97.
A sum of 5318632 shares traded at recent session while its average daily volume was at 1.26M shares. NovoCure Ltd shares reached a high of $16.5 and dropped to a low of $12.46 until finishing in the latest session at $12.54.
The one-year NVCR stock forecast points to a potential upside of 53.88. The average equity rating for NVCR stock is currently 1.75, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on NovoCure Ltd [NVCR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVCR shares is $27.19 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVCR stock is a recommendation set at 1.75. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Ladenburg Thalmann have made an estimate for NovoCure Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 08, 2025. While these analysts kept the previous recommendation, Evercore ISI raised their target price from $18 to $30. The new note on the price target was released on December 02, 2024, representing the official price target for NovoCure Ltd stock. Previously, the target price had yet another raise from $24 to $30, while H.C. Wainwright kept a Buy rating on NVCR stock.
The Price to Book ratio for the last quarter was 4.01, with the Price to Cash per share for the same quarter was set at 8.20.
NVCR Stock Performance Analysis:
NovoCure Ltd [NVCR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.64. With this latest performance, NVCR shares dropped by -26.24% in over the last four-week period, additionally sinking by -53.25% over the last 6 months – not to mention a drop of -57.92% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVCR stock in for the last two-week period is set at 24.10, with the RSI for the last a single of trading hit 1.02, and the three-weeks RSI is set at 0.93 for NovoCure Ltd [NVCR]. The present Moving Average for the last 50 days of trading for this stock 17.40, while it was recorded at 15.49 for the last single week of trading, and 20.20 for the last 200 days.
Insight into NovoCure Ltd Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and NovoCure Ltd [NVCR] shares currently have an operating margin of -27.27% and a Gross Margin at 76.53%. NovoCure Ltd’s Net Margin is presently recorded at -27.13%.
NovoCure Ltd (NVCR) Capital Structure & Debt Analysis
According to recent financial data for NovoCure Ltd. ( NVCR), the Return on Equity (ROE) stands at -48.07%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -13.91%, reflecting the company’s efficiency in generating profits from its assets. Additionally, NovoCure Ltd’s Return on Invested Capital (ROIC) is -34.89%, showcasing its effectiveness in deploying capital for earnings.
NovoCure Ltd (NVCR) Efficiency & Liquidity Metrics
Based on NovoCure Ltd’s (NVCR) latest financial statements, the Debt-to-Equity Ratio is 2.00%, indicating its reliance on debt financing relative to shareholder equity.
NovoCure Ltd (NVCR) Efficiency & Liquidity Metrics
From an operational efficiency perspective, NovoCure Ltd. (NVCR) effectively leverages its workforce, generating an average of -$114885.75 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.45% and a Quick Ratio of 1.39%, indicating strong ability to cover short-term liabilities.
NVCR Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVCR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for NovoCure Ltd go to 8.11%.
NovoCure Ltd [NVCR] Institutonal Ownership Details
There are presently around $79.29%, or 87.94% of NVCR stock, in the hands of institutional investors. The top three institutional holders of NVCR stocks are: FMR LLC with ownership of 16.14 million shares, which is approximately 14.9875%. BLACKROCK INC., holding 12.13 million shares of the stock with an approximate value of $$207.83 million in NVCR stocks shares; and BLACKROCK INC., currently with $$200.36 million in NVCR stock with ownership which is approximately 10.8601%.
